Product Description: Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90./[2]Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61.
CAS Number: 725735-28-4
Molecular Weight: 145.6 (kDa)
Compound Purity: 99.24
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: EGFR
English
Deutsch
